Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTRINSIC: Targeted Therapies in Biomarker-Positive Metastatic Colorectal Cancer
NCT04929223Phase 1Recruiting
- Sponsor
- Roche
- Start
- Oct 2021
- Primary completion
- Aug 2030
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 11
01
Overview
Phase 1, randomised, open-label trial of inavolisib, atezolizumab, tiragolumab, sy-5609 and divarasib in colorectal cancer (CRC) (10 arms), sponsored by Roche. Primary endpoint: Objective Response Rate at 84 months. Started Oct 2021; status: recruiting.
02
Drugs
inavolisibatezolizumabtiragolumabsy-5609divarasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04929223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929223.